Literature DB >> 12860727

Risk of cancer in patients with scleroderma: a population based cohort study.

C L Hill1, A-M Nguyen, D Roder, P Roberts-Thomson.   

Abstract

BACKGROUND: Previous studies have suggested an increased risk of cancer among patients with scleroderma.
OBJECTIVE: To study a population based cohort of patients with scleroderma in South Australia.
METHODS: Subjects with scleroderma were identified from the South Australian Scleroderma Registry established in 1993. All subjects on the scleroderma registry were linked to the South Australian Cancer Registry to identify all cases of cancer until 31 December 2000. Standardised incidence ratios (SIRs) for cancer for subjects with scleroderma were determined using the age- and sex-specific rates for South Australia.
RESULTS: In 441 patients with scleroderma, 90 cases of cancer were identified, 47 of which developed after inclusion on the scleroderma registry. The SIRs for all cancers among these patients were significantly increased (SIR=1.99; 95% confidence interval (95% CI) 1.46 to 2.65) compared with the cancer incidence rates for South Australia. The SIRs for lung cancer (SIR=5.9; 95% CI 3.05 to 10.31) were also significantly increased. The SIRs for all cancers among the subgroups with diffuse scleroderma (SIR=2.73; 95% CI 1.31 to 5.02) and limited scleroderma (SIR=1.85; 95% CI 1.23 to 2.68) were significantly increased.
CONCLUSIONS: This population based cohort study provides evidence that scleroderma is associated with cancer, and in particular, lung cancer. In addition, both diffuse and limited forms of scleroderma are associated with a similarly increased risk of cancer.

Entities:  

Mesh:

Year:  2003        PMID: 12860727      PMCID: PMC1754624          DOI: 10.1136/ard.62.8.728

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  20 in total

1.  Systemic sclerosis prevalence and mortality in Sydney 1974-88.

Authors:  H Englert; J Small-McMahon; K Davis; H O'Connor; P Chambers; P Brooks
Journal:  Aust N Z J Med       Date:  1999-02

2.  Scleroderma in association with the use of docetaxel (taxotere) for breast cancer.

Authors:  G Hassett; P Harnett; N Manolios
Journal:  Clin Exp Rheumatol       Date:  2001 Mar-Apr       Impact factor: 4.473

3.  [Generalized scleroderma and chromosome breakage. Demonstration of a breaking factor in patients serum].

Authors:  I Emerit; A Levy; E Housset
Journal:  Ann Genet       Date:  1973-06

4.  Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study.

Authors:  C L Hill; Y Zhang; B Sigurgeirsson; E Pukkala; L Mellemkjaer; A Airio; S R Evans; D T Felson
Journal:  Lancet       Date:  2001-01-13       Impact factor: 79.321

5.  Scleroderma in South Australia: epidemiological observations of possible pathogenic significance.

Authors:  P J Roberts-Thomson; M Jones; P Hakendorf; A A Kencana Dharmapatni; J G Walker; J G MacFarlane; M D Smith; M J Ahern
Journal:  Intern Med J       Date:  2001 May-Jun       Impact factor: 2.048

Review 6.  The establishment and utility of a population-based registry to understand the epidemiology of systemic sclerosis.

Authors:  M D Mayes
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

Review 7.  Lung cancer associated with several connective tissue diseases: with a review of literature.

Authors:  Y Yang; J Fujita; M Tokuda; S Bandoh; T Ishida
Journal:  Rheumatol Int       Date:  2001-11       Impact factor: 2.631

Review 8.  Idiopathic pulmonary fibrosis and malignancy.

Authors:  Y Ma; C K Seneviratne; M Koss
Journal:  Curr Opin Pulm Med       Date:  2001-09       Impact factor: 3.155

Review 9.  Scleroderma and malignancy. Mechanisms of interrelationship.

Authors:  Joerg Wenzel
Journal:  Eur J Dermatol       Date:  2002 May-Jun       Impact factor: 3.328

10.  Cancer and scleroderma.

Authors:  S C Duncan; R K Winkelmann
Journal:  Arch Dermatol       Date:  1979-08
View more
  57 in total

1.  Steroid-induced scleroderma renal crisis in an at-risk patient.

Authors:  Sebastian Miguel Toescu; Alex Mansell; Eoin Dinneen; Malcolm Persey
Journal:  BMJ Case Rep       Date:  2014-11-13

Review 2.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

3.  Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.

Authors:  Ami A Shah; Antony Rosen; Laura Hummers; Fredrick Wigley; Livia Casciola-Rosen
Journal:  Arthritis Rheum       Date:  2010-09

Review 4.  Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening.

Authors:  Ami A Shah; Livia Casciola-Rosen
Journal:  Curr Opin Rheumatol       Date:  2015-11       Impact factor: 5.006

5.  Genome-wide mRNA surveillance is coupled to mRNA export.

Authors:  Haley Hieronymus; Michael C Yu; Pamela A Silver
Journal:  Genes Dev       Date:  2004-10-15       Impact factor: 11.361

6.  Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival.

Authors:  Abdulla Watad; Dennis McGonagle; Nicola L Bragazzi; Shmuel Tiosano; Doron Comaneshter; Yehuda Shoenfeld; Arnon D Cohen; Howard Amital
Journal:  Oncoimmunology       Date:  2019-03-24       Impact factor: 8.110

7.  [Acral necrosis in metastatic ovarian carcinoma. A single episode of Moschowitz syndrome during gemcitabine chemotherapy].

Authors:  M J Behne; U Hauswirth; A Menz; N Brüllke; U Müllerleile; I Moll
Journal:  Hautarzt       Date:  2008-11       Impact factor: 0.751

Review 8.  Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications.

Authors:  Ami A Shah; Antony Rosen
Journal:  Curr Opin Rheumatol       Date:  2011-11       Impact factor: 5.006

9.  Malignancy in scleroderma patients from south west England: a population-based cohort study.

Authors:  Keith Siau; C J Laversuch; P Creamer; K P O'Rourke
Journal:  Rheumatol Int       Date:  2010-01-08       Impact factor: 2.631

10.  Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study.

Authors:  Eric Hachulla; Patrick Carpentier; Virginie Gressin; Elisabeth Diot; Yannick Allanore; Jean Sibilia; David Launay; Luc Mouthon; Patrick Jego; Jean Cabane; Pascal de Groote; Amélie Chabrol; Isabelle Lazareth; Loïc Guillevin; Pierre Clerson; Marc Humbert
Journal:  Rheumatology (Oxford)       Date:  2009-01-27       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.